» Articles » PMID: 3944102

Distribution of Gamma-carboxyglutamic Acid Residues in Partially Carboxylated Human Prothrombins

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1986 Feb 5
PMID 3944102
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

The role of gamma-carboxyglutamic acid in prothrombin has been examined using partially carboxylated variant prothrombins isolated from a person with a hereditary defect in vitamin K-dependent carboxylation. These species differ in gamma-carboxyglutamic acid content, distribution, and function, as monitored by metal binding properties, conformational transitions, phospholipid binding, and calcium-dependent coagulant activity (Borowski, M., Furie, B. C., Goldsmith, G. H., and Furie, B. (1985) J. Biol. Chem. 260, 9258-9264). The distribution of gamma-carboxyglutamic acids in the variant prothrombin species was determined by specific tritium incorporation into gamma-carboxyglutamic acid residues, thermal decarboxylation, and automated Edman degradation. gamma-Carboxyglutamic acid residues in the partially carboxylated prothrombins were identified by the assay of tritium in the resultant glutamic acid residues in the acarboxyprothrombins. The results indicate that variant prothrombins 1-3 are nearly homogeneous populations of partially carboxylated prothrombins. The ability of prothrombin to undergo a metal-induced conformational change and to bind to phospholipid vesicles correlated closely to the presence of a gamma-carboxyglutamic acid at residue 16. This residue is likely involved in the formation of a critical high affinity metal-binding site, possibly formed by Gla 16 and Gla 25 and/or Gla 26. A second high affinity metal-binding site, present in all of the variant prothrombin species, is defined, as an upper limit, by Gla 6, Gla 14, Gla 19, and Gla 20. This region is likely responsible for the interaction of certain of the conformation-specific antibodies to the metal-stabilized conformer of prothrombin.

Citing Articles

gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.

Gillis S, Furie B, Furie B, Patel H, Huberty M, Switzer M Protein Sci. 1997; 6(1):185-96.

PMID: 9007991 PMC: 2143515. DOI: 10.1002/pro.5560060121.


Molecular basis of hemophilia B: a defective enzyme due to an unprocessed propeptide is caused by a point mutation in the factor IX precursor.

Diuguid D, Rabiet M, Furie B, Liebman H, Furie B Proc Natl Acad Sci U S A. 1986; 83(16):5803-7.

PMID: 3461460 PMC: 386383. DOI: 10.1073/pnas.83.16.5803.


Three point mutations in the factor IX genes of five hemophilia B patients. Identification strategy using localization by altered epitopes in their hemophilic proteins.

Chen S, Thompson A, Zhang M, Scott C J Clin Invest. 1989; 84(1):113-8.

PMID: 2472424 PMC: 303960. DOI: 10.1172/JCI114130.


Cooperativity in the calcium ion-induced quenching of the intrinsic fluorescence of a series of normal and GLA-deficient bovine prothrombin fragment 1 molecules.

Malhotra O, Valencic F, Fossel E, Koehler K J Protein Chem. 1991; 10(1):31-41.

PMID: 2054061 DOI: 10.1007/BF01024653.


The long-term effects of the rodenticide, brodifacoum, on blood coagulation and vitamin K metabolism in rats.

Mosterd J, Thijssen H Br J Pharmacol. 1991; 104(2):531-5.

PMID: 1797316 PMC: 1908553. DOI: 10.1111/j.1476-5381.1991.tb12463.x.